COMMUNIQUÉS West-GlobeNewswire

Pluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform for Regenerative Medicine
26/10/2026
Partnership combines Pluri’s proprietary cell technology and clinical-development experience with ZEO’s biologics manufacturing expertise, established physician network, and sales, marketing, and educational [...]
Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis
26/10/2026
61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose (600 mg) group, highly similar to EVERLAST-A Continued favorable safety and tolerability profile consistent with the IL-23p19 class ORKA-001 on track to advance [...]
BPGbio Presents Phase 2 Glioblastoma Data Update at ESMO Congress 2026, Highlighting Median Overall Survival of 19.9 Months in MGMT-Unmethylated Patients
26/10/2026
Median overall survival of 19.9 months in patients with MGMT-unmethylated glioblastoma compares favorably with historical outcomes BPM31510 demonstrated a well-tolerated safety profile in combination with standard-of- [...]
Eledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology Kidney Week 2026 Annual Meeting
26/10/2026
Tegoprubart-treated patients demonstrated a mean improvement on the total MTSOSD-59R symptom occurrence scale at 12 months while tacrolimus-treated patients experienced a mean worsening of symptom occurrence [...]
Harrow To Report Third Quarter 2026 Financial Results After Market Close on November 9, 2026
26/10/2026
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on November 10, 2026 NASHVILLE, Tenn., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease [...]
Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights
26/10/2026
Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in November 2026 IND filing for the Enhanced Brain Delivery™ (EBD ® ) [...]
VETmAb Biosciences Announces Positive Clinical Proof-of-Concept Results for Long-Acting Anti-IL-23 Antibody in Canine Chronic Inflammatory Enteropathy
26/10/2026
In the VMB-C001a group, 77.8% of dogs were considered a treatment success, compared with 30.0% in the placebo group VMB-C001a granted eligibility for the U.S. Food and Drug Administration’s (FDA) Center for Veterinary [...]
Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026
26/10/2026
50% Confirmed Objective Response Rate (ORR) with All Responses Ongoing in an Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2026 Unprecedented Efficacy in Both Refractory Undifferentiated [...]
TILT Biotherapeutics Presents Encouraging Phase 1b Results in Ovarian Cancer at ESMO 2026
26/10/2026
Four of nine evaluable patients responded to TILT-123 combined with pembrolizumab and pegylated liposomal doxorubicin, including two complete responses HELSINKI, Finland, Oct. 26, 2026 (GLOBE NEWSWIRE) -- TILT [...]
Tonix Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 9, 2026
26/10/2026
BERKELEY HEIGHTS, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial-stage biotechnology company, today announced that [...]
Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026
26/10/2026
NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its third [...]
Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness
26/10/2026
Updated agreement expands 2020 procurement agreement with BARDA for Regeneron's first-in-class antibody treatment for Orthoebolavirus zairense , adding value of approximately $270 million TARRYTOWN, N.Y., Oct. 26, 2026 [...]
Changes in Orion Group’s Executive Team as of 1 January 2027
26/10/2026
ORION CORPORATION STOCK EXCHANGE RELEASE - CHANGES BOARD/MANAGEMENT/AUDITORS 26 October 2026 at 13.00 EET Changes in Orion Group’s Executive Team as of 1 January 2027 To accelerate the implementation of its strategy and [...]
Serapha Bio Announces Positive Interim Safety and Efficacy Data from the SERP-01 Investigator-Initiated Trial Presented at the ERS Alpha-1 Antitrypsin Conference 2026
26/10/2026
Single administration of SERP-01 was associated with increases in total serum AAT above the protective threshold with durable correction out to 10 months Elastase inhibition assay results showed serum approached [...]
Kraig Biocraft Laboratories Launches Performance Yarn Development Program and Ships Spider Silk to Yarn and Aerospace Innovator
26/10/2026
Initiative Builds on First Commercial Yarn Shipment to Create New Constructions and Blends for the Next Generation of Fabrics and Apparel ANN ARBOR, Mich., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, [...]
MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic Cancer
26/10/2026
Single agent lorigerlimab demonstrated encouraging preliminary clinical activity in clear cell gynecologic cancer (CCGC) with a confirmed ORR of 25% and a DCR of 44% Safety profile was manageable; further dose [...]
Davion Healthcare Announces US$25 Million Acquisition of Humaskan Medical Technology IP
26/10/2026
Acquisition adds battery-free smart wound dressing and two-minute multi-marker screening test to Davion’s growing healthcare portfolio DUBLIN, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Davion Healthcare Plc (Nasdaq: DAVI) (" [...]
BrainsWay Expands U.S. Insurance Coverage for Deep TMS™ Treatment of OCD to Over 118 Million Lives
26/10/2026
BURLINGTON, Mass. and JERUSALEM, Oct. 26, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today [...]
Medicus Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
26/10/2026
Nasdaq closes the minimum bid price matter confirming that the Company has regained compliance PHILADELPHIA, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a precision [...]

Pages